<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 27, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749017</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-00018</org_study_id>
    <nct_id>NCT04749017</nct_id>
  </id_info>
  <brief_title>The Potential Effect of Neuravena on Wellness/Wellbeing During Smoking Reduction/Cessation Experience</brief_title>
  <acronym>FUMA</acronym>
  <official_title>A Double Blind, Randomized, Controlled Study for the Potential Effect of Neuravena on Wellness/Wellbeing During Smoking Reduction/Cessation Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-centre, double blind placebo controlled, parallel study and stratified by the number&#xD;
      of cigarettes consumed and the desire to smoke, according to the Richmond Scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of Neuravena on wellness/wellbeing during smoking reduction/cessation&#xD;
      experience&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled carbon monoxide</measure>
    <time_frame>Carbon monoxide change from baseline to 12 weeks after product consumption</time_frame>
    <description>Measured by a cooximeter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cigarettes smoked</measure>
    <time_frame>Day 1, at 4, 8 and 12 weeks later</time_frame>
    <description>Daily cigarettes per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to reduce daily cigarettes</measure>
    <time_frame>Day 1</time_frame>
    <description>Richmond test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Series</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Hematological parameters (red series)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Series</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Hematological parameters (white series)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine test</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Basic urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>It will be measured for 3 days before and after the consumption time (60 days) with the experimental product and the placebo product.</time_frame>
    <description>Measured by accelerometry, with Actigraph wGT3X-BT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotinine</measure>
    <time_frame>It is measured at the beginning of the study and a month after the end of the consumption of the product</time_frame>
    <description>Measured by urine and blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Measured by urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopyrin</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Measured by urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>It is measured at the beginning of the study, one month and at the end of the consumption of the product (2 months)</time_frame>
    <description>Measured by saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological evaluation</measure>
    <time_frame>Day 1</time_frame>
    <description>DASS21 Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellbeing / wellness</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>WHOQOL BREF test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive test panel</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>COMPASS test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of craving level</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>Using a visual scale where 0 is no desire to smoke and 10 is a strong desire to smoke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>SF-36 test health questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief questionnaire of smoking urges</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>QSU-Brief/Tiffany test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck for depression</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Test to measure the level of depression of the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress scale</measure>
    <time_frame>It is measured at the beginning of the study, one month and at the end of the consumption of the product (2 months)</time_frame>
    <description>Test to measure the level of stress of the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety questionnaire</measure>
    <time_frame>It is measured at the beginning of the study, one month and at the end of the consumption of the product (2 months).</time_frame>
    <description>Test STAI to measure the level of anxiety of the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test fof nicotine dependence</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Fagerstrom test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine withdrawal scale</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>The Minnesota test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life panel</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Using a visual scale where 0 is bad and 10 is very good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THC</measure>
    <time_frame>Day 1 and 8 weeks later</time_frame>
    <description>Drug test. It will be measured if it is positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amphetamines</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>Drug test. It will be measured if it is positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methamphetamines</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>Drug test. It will be measured if it is positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>Drug test. It will be measured if it is positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioids</measure>
    <time_frame>It is measured after the consumption of the product (2 months).</time_frame>
    <description>Drug test. It will be measured if it is positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms questionnaire</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Symptoms they have suffered in the last week. Using a visual scale, where 0 is a null and 10 is a very intense symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse events</measure>
    <time_frame>Day 1, at 8 and 12 weeks later</time_frame>
    <description>Secondary effects of the supplements used in this study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Smoking Reduction</condition>
  <arm_group>
    <arm_group_label>Experimental group (neuravena)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption for 60 days of Neuravena (900mg)&#xD;
Two capsules per day orally for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules per day orally for 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplement consumption</intervention_name>
    <description>The experimental product consumption time was 60 days and the control consumption time was 60 days.</description>
    <arm_group_label>Experimental group (neuravena)</arm_group_label>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age: 18-65 YO)&#xD;
&#xD;
          -  Willingness to reduce/quit daily cigarettes (Richmond test)&#xD;
&#xD;
          -  Regular smokers: ≥10 CPD for the last 6 months (mean of ~16)&#xD;
&#xD;
          -  At least 6 months of smoking&#xD;
&#xD;
          -  Exhaled CO level≥10 ppm&#xD;
&#xD;
          -  Healthy adults:&#xD;
&#xD;
               1. Normal blood profile at screening&#xD;
&#xD;
               2. Subject is in a good physical health as established by medical history, vital&#xD;
                  signs, self-declaration and physical examination&#xD;
&#xD;
               3. Without depression/ anxiety or stress (based on a psychological evaluation and&#xD;
                  DASS21 questionnaire)&#xD;
&#xD;
          -  Able to participate fully in all aspects of the study and had understood and signed&#xD;
             the informed consent&#xD;
&#xD;
          -  Negative drug test (THC, Amphetamines, Methamphetamines, Cocaine and Opioids)&#xD;
&#xD;
          -  For women: Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any mineral/vitamin/drug or other supplements during the past month prior to&#xD;
             study&#xD;
&#xD;
          -  Participate in another clinical trial in the last 6 months&#xD;
&#xD;
          -  Using (past 30 days) other smoking cessation aids, for example treatments for tobacco&#xD;
             dependence or an investigational drug&#xD;
&#xD;
          -  Smoke other nicotine-containing products such as hookah smokeless tobacco or&#xD;
             electronic cigarettes&#xD;
&#xD;
          -  Allergic or intolerance to one of the ingredients of the investigated product&#xD;
&#xD;
          -  Diagnosed or treated for mental illness/ disorder in the past year&#xD;
&#xD;
          -  Recent history (past year) of alcohol or drug abuse or dependence&#xD;
&#xD;
          -  Reported any active/chronic disease (such as: Celiac disease/active peptic ulcer) or&#xD;
             chronic medications (except Hyperlipidaemia or hypertension that are stable on&#xD;
             medications)&#xD;
&#xD;
          -  Any other laboratory abnormality, medical condition or psychiatric disorder which in&#xD;
             the Investigator's opinion may adversely affect the subject's ability to complete the&#xD;
             study or its measures or which may pose significant risk to the subject&#xD;
&#xD;
          -  Pregnant, lactating women or women that plan to get pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fco Javier López Román</last_name>
      <phone>968278523</phone>
      <email>jlroman@ucam.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Wellbeing</keyword>
  <keyword>Wellness</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

